par Partridge, Ann A.H.;Gelber, Shari;Piccart-Gebhart, Martine
;Focant, Florine;Scullion, Matthew;Holmes, Eileen;Winer, Eric E.P.;Gelber, Richard
Référence Journal of clinical oncology, 31, 21, page (2692-2698)
Publication Publié, 2013-07

Référence Journal of clinical oncology, 31, 21, page (2692-2698)
Publication Publié, 2013-07
Article révisé par les pairs
Résumé : | Previous research has suggested that young age at diagnosis is an independent risk factor for breast cancer recurrence and death. No prior studies have adequately controlled for human epidermal growth factor receptor 2 (HER2) status or anti-HER2 treatment. We sought to evaluate whether age was a prognostic or predictive factor in the HERA trial. |